AWM Investment Company Inc. Boosts Stock Holdings in Nkarta, Inc. $NKTX

Key Points

• AWM Investment Company Inc. increased its stake in Nkarta, Inc. by 150%, now owning 1 million shares worth approximately $1.84 million.
• Institutional investors collectively own 80.54% of Nkarta's stock, indicating strong institutional interest in the company.
• Analysts have mixed views on Nkarta, with varying target prices ranging from $10.00 to $14.00, but the consensus rating is a "Buy".

AWM Investment Company Inc. raised its holdings in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 150.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,000,000 shares of the company's stock after purchasing an additional 600,000 shares during the period. AWM Investment Company Inc. owned 1.41% of Nkarta worth $1,840,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Nkarta in the 1st quarter worth approximately $32,000. Bank of America Corp DE boosted its stake in shares of Nkarta by 110.1% in the 4th quarter. Bank of America Corp DE now owns 380,444 shares of the company's stock worth $947,000 after buying an additional 199,345 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Nkarta by 26.1% in the 4th quarter. Deutsche Bank AG now owns 43,157 shares of the company's stock worth $107,000 after buying an additional 8,946 shares during the last quarter. Nuveen Asset Management LLC lifted its position in Nkarta by 18.3% during the fourth quarter. Nuveen Asset Management LLC now owns 140,113 shares of the company's stock valued at $349,000 after purchasing an additional 21,627 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in Nkarta by 4.1% during the fourth quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock valued at $561,000 after acquiring an additional 8,883 shares during the period. Institutional investors own 80.54% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price target on shares of Nkarta in a report on Wednesday, August 13th. Wall Street Zen raised shares of Nkarta from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. William Blair reaffirmed a "market perform" rating on shares of Nkarta in a research note on Thursday, May 15th. Mizuho cut their price target on Nkarta from $16.00 to $14.00 and set an "outperform" rating for the company in a report on Tuesday, June 10th. Finally, Stifel Nicolaus dropped their target price on shares of Nkarta from $14.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Nkarta currently has a consensus rating of "Buy" and an average target price of $13.60.

Nkarta Stock Up 6.1%

NKTX traded up $0.13 on Friday, reaching $2.26. The company had a trading volume of 436,884 shares, compared to its average volume of 519,375. Nkarta, Inc. has a 1 year low of $1.31 and a 1 year high of $6.63. The stock has a market capitalization of $160.52 million, a PE ratio of -1.53 and a beta of 0.76. The stock has a 50-day moving average price of $2.05 and a 200-day moving average price of $1.89.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.06. As a group, analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.